Eur J Cancer. 1998 Aug;34(9):1368-74.

Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.

Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U, Ingvar C, Malmström P, Andersson R, Karlsson M, Willman K, Wist E, Bjelkengren G, Westberg R.

Source

Department of Experimental Oncology, Karolinska Hospital, Stockholm, Sweden.

Abstract

In a multicentre phase III study of disseminated malignant melanoma performed in Sweden and Norway, 326 patients were randomised to receive treatment with the combination dacarbazine [DTIC] (D) and vindesine (V) with or without the addition of cisplatin (P). D was given intravenously (i.v.) at a dose of 250 mg/m2 days 1-5 every 4 weeks and V was given i.v. at a dose of 3.0 mg/m2 day 1 weekly. P was given i.v. at a dose of 100 mg/m2 day 1 every 4 weeks. There was no statistically significant difference in overall survival between the treatment arms (P = 0.22). Increased toxicity was observed in the treatment arm containing P of which leucopenia, alopecia and nausea/vomiting were the most pronounced. The median time to progression was significantly longer in patients treated with DVP (4.2 versus 2.2 months, P = 0.007). In conclusion, adding P to DV did not change overall survival but did significantly increase toxicity.

PMID:: 9849419; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). [Melanoma Res. 1999]
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Sertoli MR, Queirolo P, Bajetta E, Del Vecchio M, Comella G, Barduagni L, Bernengo MG, Vecchio S, Criscuolo D, Bufalino R, et al. Melanoma Res. 1999 Oct; 9(5):503-9.
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. [J Clin Oncol. 1999]
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, et al. J Clin Oncol. 1999 Sep; 17(9):2745-51.
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). [Br J Cancer. 2001]
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, et al. Br J Cancer. 2001 Apr 20; 84(8):1036-42.
Review Establishment of the standard regimen for non-small-cell lung cancer in Japan. [Oncology (Williston Park). 2001]
Review Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N. Oncology (Williston Park). 2001 Jan; 15(1 Suppl 1):13-8.
Review Biochemotherapy in the treatment of metastatic melanoma in selected patients. [Clin Transl Oncol. 2009]
Review Biochemotherapy in the treatment of metastatic melanoma in selected patients.
González Astorga B, Jiménez Rubiano B, Delgado Pérez JR, Valdivia Bautista J, Sánchez Toro C, González Flores E, Luque Caro R, Castellón Rubio V. Clin Transl Oncol. 2009 Jun; 11(6):382-6.

See reviews... See all...

Cited by 3 PubMed Central articles

Malignant melanoma (metastatic). [Clin Evid (Online). 2008]
Malignant melanoma (metastatic).
Larkin J, Gore M. Clin Evid (Online). 2008 Aug 22; 2008. Epub 2008 Aug 22.
Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation. [J Exp Clin Cancer Res. 2009]
Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.
Ristić-Fira AM, Korićanac LB, Zakula JJ, Valastro LM, Iannolo G, Privitera G, Cuttone G, Petrović IM. J Exp Clin Cancer Res. 2009 Apr 9; 28:50. Epub 2009 Apr 9.
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. [Br J Cancer. 2003]
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J. Br J Cancer. 2003 Oct 20; 89(8):1517-23.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated mal...
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.
Eur J Cancer. 1998 Aug ;34(9):1368-74.

PubMed
Functional food science and behaviour and psychological functions.
Functional food science and behaviour and psychological functions.
Br J Nutr. 1998 Aug ;80 Suppl 1:S173-93.

PubMed
The effect that time, touch and environment have upon bacterial contamination of...
The effect that time, touch and environment have upon bacterial contamination of instruments during surgery.
Ann Surg. 1976 Nov ;184(5):642-4.

PubMed
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A p...
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Ann Rheum Dis. 1998 Sep ;57(9):545-9.

PubMed
Periarthritis of the shoulder. I. Aetiological considerations with particular re...
Periarthritis of the shoulder. I. Aetiological considerations with particular reference to personality factors.
Ann Rheum Dis. 1976 Jun ;35(3):213-9.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information